These results demonstrate that suppressing GCS overexpression sensitizes resistant cancer cells to therapeutic agents, such as doxorubicin whose therapeutic efficiency is associated with ceramide actuation [11], [41], [42]. The gene discussed is UGCG; the disease is cancer.